EU green light for Merck, Pfizer’s Bavencio
Adult patients with metastatic Merkel cell carcinoma (mMCC) in Europe stand to gain access to the first immunotherapy to treat the disease following regulatory approval of Merck and Pfizer’s Bavencio.
Read More
